These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 5998360)

  • 1. [Contribution to the problem of hemochromatosis].
    Bruns W; Michaelis D; Takác A; Langsch HG
    Dtsch Z Verdau Stoffwechselkr; 1966 Feb; 25(6):363-70. PubMed ID: 5998360
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 3. Desferal therapy in iron storage disease.
    Thompson RB; Owen DM; Bell WN
    Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380
    [No Abstract]   [Full Text] [Related]  

  • 4. Intramuscular deferoxamine in hereditary hemochromatosis.
    Polo-Romero FJ
    Am J Hematol; 2006 Mar; 81(3):225-6. PubMed ID: 16493613
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic results in the treatment of primary and secondary hemochromatoses with Desferal].
    Wöhler F
    Blut; 1967 Apr; 15(1):33-42. PubMed ID: 6025965
    [No Abstract]   [Full Text] [Related]  

  • 6. [Iron metabolism and its exploration in clinical biology].
    Brissot P; Pigeon C; Moirand R; Guyader D; Mendler MH; Sapey T; Deugnier Y; Lescoat G; Loréal O
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():5-10. PubMed ID: 9827209
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hemochromatosis in the age of genetics].
    Buffet C
    Presse Med; 2007 Sep; 36(9 Pt 2):1269-70. PubMed ID: 17560763
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent advances in iron metabolism.
    Powell LW; Halliday JW; Bassett ML
    Aust N Z J Med; 1979 Oct; 9(5):578-83. PubMed ID: 294916
    [No Abstract]   [Full Text] [Related]  

  • 9. Recognition and treatment of iron overload.
    Brown EB
    Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F; Lessmann J
    Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3.
    Drake SF; Morgan EH; Herbison CE; Delima R; Graham RM; Chua AC; Leedman PJ; Fleming RE; Bacon BR; Olynyk JK; Trinder D
    Am J Physiol Gastrointest Liver Physiol; 2007 Jan; 292(1):G323-8. PubMed ID: 16935854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Disorders of iron metabolism in liver patients].
    Stromeyer G
    Internist (Berl); 1966 Jan; 7(1):33-42. PubMed ID: 4861683
    [No Abstract]   [Full Text] [Related]  

  • 13. [Iron kinetics in hemochromatosis].
    Najean Y; Dresch C
    Ann Biol Clin (Paris); 1972; 30(4):379-89. PubMed ID: 5082972
    [No Abstract]   [Full Text] [Related]  

  • 14. [Myocardiopathy caused by iron deposition. Treatment with chelating agents].
    Rodríguez Reguero JJ; Iglesias Cubero G; Espolita Santos A; López de la Iglesia JM; Enríquez Martín J; Tomás Mauri J; López-Negrete L
    Rev Esp Cardiol; 1985; 38(5):356-7. PubMed ID: 4081244
    [No Abstract]   [Full Text] [Related]  

  • 15. [Specific treatment of excessive iron deposition in the tissues].
    Plachecka-Gutowska M; Mikolajew M
    Pol Arch Med Wewn; 1965; 35(1):111-7. PubMed ID: 5900073
    [No Abstract]   [Full Text] [Related]  

  • 16. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and biochemical expression of the genetic abnormality in idiopathic hemochromatosis.
    Valberg LS; Lloyd DA; Ghent CN; Flanagan PR; Sinclair NR; Stiller CR; Chamberlain MJ
    Gastroenterology; 1980 Nov; 79(5 Pt 1):884-92. PubMed ID: 7419013
    [No Abstract]   [Full Text] [Related]  

  • 18. Normal transferrin saturation in hemochromatosis.
    Barton JC; Bertoli LF; Janich MR; Arthur MW; Alford TJ
    Hosp Pract (Off Ed); 1991 Apr; 26 Suppl 3():46-8. PubMed ID: 2010491
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical usefulness of iron chelating agents.
    Waxman HS; Brown EB
    Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246
    [No Abstract]   [Full Text] [Related]  

  • 20. [Mechanism of action of desferrioxamine].
    Kaszewska-Jablońska I; Zielińska W
    Wiad Lek; 1975 Jan; 28(2):89-96. PubMed ID: 1111247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.